Michael F. Mahoney
Summary
Michael F. Mahoney has led Boston Scientific as President and Chief Executive Officer since November 2012 and has also served as Chairman since May 2016. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2026-Boston-Scientific-proxy-statement.pdf.coredownload.pdf?utm_source=openai))
Biography
Mahoney joined Boston Scientific as President in October 2011 and became President, Chief Executive Officer, and a director in November 2012. He became Chairman of the Board in May 2016. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2026-Boston-Scientific-proxy-statement.pdf.coredownload.pdf?utm_source=openai)) Before Boston Scientific, Mahoney was Worldwide Chairman of Johnson & Johnson’s Medical Devices and Diagnostics division and previously led its DePuy orthopedics and neurosciences franchise. Earlier in his career, he was President and Chief Executive Officer of Global Healthcare Exchange and held several leadership positions at General Electric Medical Systems, including General Manager of its Healthcare Information Technology business. He holds a finance degree from the University of Iowa and an MBA from Wake Forest University, and serves as a director of CVS Health. ([bostonscientific.com](https://www.bostonscientific.com/en-US/about-us/leadership/mike-mahoney.html?utm_source=openai))
Notable achievements
- Oversaw Boston Scientific during a period in which reported 2025 net sales reached $20.074 billion; the company reported 16.6% average GAAP net-sales growth from 2023 through 2025. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2026-Boston-Scientific-proxy-statement.pdf.coredownload.pdf?utm_source=openai))
- Helped expand the company’s medical-device portfolio through acquisitions including Apollo Endosurgery, which added endoluminal surgery and endobariatric technologies. ([news.bostonscientific.com](https://news.bostonscientific.com/2022-11-29-Boston-Scientific-Announces-Agreement-to-Acquire-Apollo-Endosurgery%2C-Inc?utm_source=openai))
- Supported the launch and commercialization of the Farapulse Pulsed Field Ablation System, which launched in the United States in early 2024 and was identified by the company as a major driver of electrophysiology growth. ([publicnow.com](https://www.publicnow.com/view/E7663A90B4DAFBFB842AE0D0848DC085CED11F83?utm_source=openai))
- Built a broad operating platform spanning cardiovascular, electrophysiology, gastrointestinal, urological, neurological, and other minimally invasive medical technologies. ([bostonscientific.com](https://www.bostonscientific.com/en-US/about-us/leadership/mike-mahoney.html?utm_source=openai))
Problem areas / controversies
- During Mahoney’s tenure, the FDA classified a recall involving certain Accolade pacemakers after the devices were found to have an increased risk of entering Safety Mode because of a battery-related manufacturing issue. ([accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/resCollection_2.cfm?ID=211663&utm_source=openai))
- Boston Scientific also faced an FDA safety alert involving certain defibrillation leads; as of July 24, 2025, the company had reported 386 serious injuries and 16 patient deaths associated with the issue. This was a company product-safety matter, not a finding of personal misconduct by Mahoney. ([fda.gov](https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/update-alert-defibrillation-lead-issue-boston-scientific?utm_source=openai))
- The company’s filings disclose ongoing product-liability, intellectual-property, commercial, securities, and regulatory proceedings, creating continuing legal and compliance exposure during his leadership. ([publicnow.com](https://www.publicnow.com/view/E7663A90B4DAFBFB842AE0D0848DC085CED11F83?utm_source=openai))